Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

Benzinga Newsdesk www.benzinga.com Positive 88.3%

Neg 0% Neu 0% Pos 88.3%

Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.